Ubiquigent wins o2h Kickstarter Award

o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery. 

As part of the program, o2h discovery will provide Ubiquigent with access to chemists and associated end-to-end expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.

The development of DUB-targeting compounds is accelerating rapidly as implication, knowledge and understanding of the roles of DUBs in disease are becoming increasingly understood.  DUB inhibitors have begun to enter clinical development, and significant investment is being directed towards the development of other DUB-related modalities such as DUB-Targeting Chimeras (DUBTACs) and DUB-Targeting Proteolysis Targeting Chimeras (PROTACs).  Despite these advances, access to novel DUB-targeting compounds with which to initiate programs remains challenging.

The development of DUB-targeting compounds is accelerating rapidly as implication, knowledge and understanding of the roles of DUBs in disease are becoming increasingly understood.  DUB inhibitors have begun to enter clinical development, and significant investment is being directed towards the development of other DUB-related modalities such as DUB-Targeting Chimeras (DUBTACs) and DUB-Targeting Proteolysis Targeting Chimeras (PROTACs).  Despite these advances, access to novel DUB-targeting compounds with which to initiate programs remains challenging.

Rishi Shah, Head of Chemistry, Ubiquigent, commented:

We are delighted to be the latest recipient of an o2h Kickstarter Award. It represents an invaluable level of support and comes at a key point in our development. A major challenge in the DUB field is access to novel, high-quality DUB-targeting compounds – the cornerstone of new programmes. o2h’s deep expertise in insight-driven drug discovery, synthetic chemistry, and library synthesis, combined with their established track record in accelerating early-stage drug discovery, perfectly complements our need for reliable and rapid compound synthesis and iterative optimisation. The opportunity to work closely with o2h will fast-track our progress this year and support our strategy of enabling our partners in the field of DUB-focused drug discovery.

Sunil Shah, Co-founder, o2h discovery, said:

As a recognised leader in supporting DUB-focused drug discovery, Ubiquigent is a worthy recipient of an o2h kickstarter award. o2h discovery is looking forward to working with the team at Ubiquigent to apply our combined technology, expertise and capabilities to the exciting DUB family of enzymes, a field which has shown considerable growth in recent years.